drugset / Trial / NCT05298176
Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors
NaSingle-groupOpen-labelTreatment
Summary
The aim of the COMBINATION trial is to prospectively study the sequential approach of using afatinib combined with a short course of chemotherapy, followed by osimertinib, upon progression and acquisition of a T790M mutation, also combined with a short course of chemotherapy.
Timeline
- Start
- 2022-01-04
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 30 mg | Oral |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Osimertinib | Small molecule | 80 mg | — |
| Subject | Pemetrexed | Small molecule | — | — |